Phase 2
N=10
Effect of Inhaled Albuterol in Pulmonary Hypertension
Pulmonary Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT03270332 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Aug 2021
Primary outcome: Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Albuterol (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Miami
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Pulmonary Artery Pressure (MPAP) |
6.5; 4.3 | — |
| SECONDARY Change in Pulmonary Vascular Resistance (PVR) |
217; 108 | — |
Summary
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.
Eligibility Criteria
Inclusion Criteria
- A Mean Pulmonary Artery Pressure >25mmHg, Pulmonary Vascular Resistance >3 wood/units and pulmonary arterial wedge pressure 150 and/or diastolic arterial BP>100 on the experiment day
- A resting O2 saturation of 35 kg/m2 and/or a diagnosis of obstructive sleep apnea
- Use of inhaled or intravenous pulmonary vasodilators
Data sourced from ClinicalTrials.gov (NCT03270332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.